Barrington Research Assumes Coverage On Opko Health On Positive Outlook

In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on

with an Outperform rating and $19.00 price target. In the report, Barrington Research noted, "We are assuming coverage of OPKO Health due to an analyst transition. Headquartered in Miami, Florida OPKO primarily focuses on point-of-care diagnostics, novel molecular diagnostics, and pharmaceuticals...Led by long-time healthcare executive Phillip Frost, OPKO has many additional shots on goal even beyond the opportunities within its currently commercialized product portfolio and its front-burner pipeline products, Rayaldee, and hGH-CTP. We have included information on pages 2 and 3, which illustrates key aspects of the current product portfolio as well as the depth of the product pipeline." Opko Health closed on Wednesday at $13.88.